Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
about
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not goldImpact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer.Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
P2860
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Health Economics and Radium-22 ...... matic Review of the Literature
@ast
Health Economics and Radium-22 ...... matic Review of the Literature
@en
Health Economics and Radium-22 ...... matic Review of the Literature
@nl
type
label
Health Economics and Radium-22 ...... matic Review of the Literature
@ast
Health Economics and Radium-22 ...... matic Review of the Literature
@en
Health Economics and Radium-22 ...... matic Review of the Literature
@nl
prefLabel
Health Economics and Radium-22 ...... matic Review of the Literature
@ast
Health Economics and Radium-22 ...... matic Review of the Literature
@en
Health Economics and Radium-22 ...... matic Review of the Literature
@nl
P2093
P2860
P31
P356
P1476
Health Economics and Radium-22 ...... matic Review of the Literature
@en
P2093
Arpad Totth
Carsten Nieder
Erik R. Traasdahl
Jan Abel Olsen
P2860
P356
10.5539/GJHS.V8N4P1
P407
P5008
P577
2015-07-30T00:00:00Z